These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37248544)

  • 1. Development and validation of sensitive BCR::ABL1 fusion gene quantitation using next-generation sequencing.
    Lee H; Seo J; Shin S; Lee ST; Choi JR
    Cancer Cell Int; 2023 May; 23(1):106. PubMed ID: 37248544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib.
    Kitamura H; Tabe Y; Ai T; Tsuchiya K; Yuri M; Misawa S; Horii T; Kawaguchi A; Ohsaka A; Kimura S
    PLoS One; 2019; 14(3):e0207170. PubMed ID: 30835732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Committed change of real-time quantitative PCR to droplet digital PCR for monitoring
    Kongruang A; Limsuwanachot N; Magmuang S; Areesirisuk P; Niparuck P; Siriboonpiputtana T; Rerkamnuaychoke B
    Hematology; 2023 Dec; 28(1):2256199. PubMed ID: 37695125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analytical Validation of a Highly Sensitive, Multiplexed Chronic Myeloid Leukemia Monitoring System Targeting BCR-ABL1 RNA.
    Brown JT; Beldorth IJ; Laosinchai-Wolf W; Fahey ME; Jefferson KL; Ruskin AK; Roth JJ; Cai L; Watt CD; Press RD; Yang F; Hedges JB; Andruss BF
    J Mol Diagn; 2019 Jul; 21(4):718-733. PubMed ID: 31026597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel BCR-ABL1 fusion gene identified by next-generation sequencing in chronic myeloid leukemia.
    Lyu X; Yang J; Wang X; Hu J; Liu B; Zhao Y; Guo Z; Liu B; Fan R; Song Y
    Mol Cytogenet; 2016; 9():47. PubMed ID: 27350795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative BCR-ABL1 RQ-PCR fusion transcript monitoring in chronic myelogenous leukemia.
    Moore FR; Rempfer CB; Press RD
    Methods Mol Biol; 2013; 999():1-23. PubMed ID: 23666687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase.
    Machova Polakova K; Kulvait V; Benesova A; Linhartova J; Klamova H; Jaruskova M; de Benedittis C; Haferlach T; Baccarani M; Martinelli G; Stopka T; Ernst T; Hochhaus A; Kohlmann A; Soverini S
    J Cancer Res Clin Oncol; 2015 May; 141(5):887-99. PubMed ID: 25367136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One-Step Multiplexed Droplet Digital Polymerase Chain Reaction for Quantification of p190 BCR-ABL1 Fusion Transcript in B-Lymphoblastic Leukemia.
    Martinez RJ; Kang Q; Nennig D; Bailey NG; Brown NA; Betz BL; Tewari M; Thyagarajan B; Bachanova V; Mroz P
    Arch Pathol Lab Med; 2022 Jan; 146(1):92-100. PubMed ID: 33769465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel BCR-ABL1 fusion and leukemic mutations of SETBP1, PAX5, and TP53 detected by next generation sequencing in chronic myeloid leukemia.
    Fu S; Hu Y; Fu Y; Chen F; Liu X; Zhang M; Wang X; Tu S; Zhang J
    Cancer Biol Ther; 2016 Oct; 17(10):1003-1009. PubMed ID: 27611742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of BCR-ABL1 transcripts on the International Scale in the United States: current status and best practices.
    Arora R; Press RD
    Leuk Lymphoma; 2017 Jan; 58(1):8-16. PubMed ID: 27412040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.
    Soverini S; De Benedittis C; Castagnetti F; Gugliotta G; Mancini M; Bavaro L; Machova Polakova K; Linhartova J; Iurlo A; Russo D; Pane F; Saglio G; Rosti G; Cavo M; Baccarani M; Martinelli G
    BMC Cancer; 2016 Aug; 16():572. PubMed ID: 27485109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid Leukemia.
    Alikian M; Whale AS; Akiki S; Piechocki K; Torrado C; Myint T; Cowen S; Griffiths M; Reid AG; Apperley J; White H; Huggett JF; Foroni L
    Clin Chem; 2017 Feb; 63(2):525-531. PubMed ID: 27979961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic Myeloid Leukemia with an e6a2
    Crampe M; Haslam K; Groarke E; Kelleher E; O'Shea D; Conneally E; Langabeer SE
    Case Rep Hematol; 2017; 2017():9071702. PubMed ID: 29123930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial.
    Atallah E; Schiffer CA; Radich JP; Weinfurt KP; Zhang MJ; Pinilla-Ibarz J; Kota V; Larson RA; Moore JO; Mauro MJ; Deininger MWN; Thompson JE; Oehler VG; Wadleigh M; Shah NP; Ritchie EK; Silver RT; Cortes J; Lin L; Visotcky A; Baim A; Harrell J; Helton B; Horowitz M; Flynn KE
    JAMA Oncol; 2021 Jan; 7(1):42-50. PubMed ID: 33180106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of a rapid one-step high sensitivity real-time quantitative PCR system for detecting major BCR-ABL1 mRNA on an International Scale.
    Yoshida C; Nakamae H; Fletcher L; Koga D; Sogabe T; Matsumura I; Kanakura Y; Branford S; Naoe T
    Springerplus; 2016; 5():569. PubMed ID: 27247866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A rare e13a3 (b2a3) BCR-ABL1 fusion transcript with normal karyotype in chronic myeloid leukemia: The challenges in diagnosis and monitoring minimal residual disease (MRD).
    Duan MH; Li H; Cai H
    Leuk Res; 2017 Aug; 59():8-11. PubMed ID: 28527402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular techniques for the personalised management of patients with chronic myeloid leukaemia.
    Alikian M; Gale RP; Apperley JF; Foroni L
    Biomol Detect Quantif; 2017 Mar; 11():4-20. PubMed ID: 28331814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reverse transcription with random pentadecamer primers improves the detection limit of a quantitative PCR assay for BCR-ABL transcripts in chronic myeloid leukemia: implications for defining sensitivity in minimal residual disease.
    Ross DM; Watkins DB; Hughes TP; Branford S
    Clin Chem; 2008 Sep; 54(9):1568-71. PubMed ID: 18641042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of BCR-ABL1 quantification in peripheral blood and bone marrow using an International Scale-standardized assay for assessment of deep molecular response in chronic myeloid leukemia.
    Greiner G; Ratzinger F; Gurbisz M; Witzeneder N; Taghizadeh H; Mustafa SGK; Mitterbauer-Hohendanner G; Esterbauer H; Mannhalter C; Sperr WR; Valent P; Hoermann G
    Clin Chem Lab Med; 2020 Jul; 58(8):1214-1222. PubMed ID: 32084002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of
    Uzoma IC; Taiwo IA; Nna EO; Durosinmi MA; Ukaejiofo EO
    Niger J Clin Pract; 2019 Jan; 22(1):51-55. PubMed ID: 30666020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.